Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Journal of Applied Gerontology : the Official Journal of the Southern Gerontological Society|March 24, 2016
Exploratory and Confirmatory Factor Analyses of Delirium Symptoms in a Sample of Nursing Home ResidentsPatience Moyo, Ting-Ying Huang, Linda Simoni-Wastila, et al.Pharmacoepidemiology and Drug Safety|February 19, 2020
Translating claims-based CHA2 DS2 -VaSc and HAS-BLED to ICD-10-CM: Impacts of mapping strategiesMichael Webster-Clark, Ting-Ying Huang, Laura Hou, et al.The Journal of Clinical Psychiatry|June 5, 2019
Antipsychotic Use and Stroke: A Retrospective Comparative Study in a Non-Elderly PopulationLockwood G Taylor, Genna Panucci, Andrew D Mosholder, et al.Pharmacoepidemiology and Drug Safety|November 19, 2019
Quantifying how small variations in design elements affect risk in an incident cohort study in claimsRima Izem, Ting-Ying Huang, Laura Hou, et al.Journal of General Internal Medicine|September 29, 2020
Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with WarfarinMarie Bradley, Emily C Welch, Efe Eworuke, et al.JAMA Internal Medicine|October 5, 2018
Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed DatabaseJie Li, Genna Panucci, David Moeny, et al.Journal of the American Geriatrics Society|August 28, 2015
Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related DementiasTing-Ying Huang, Yu-Jung Wei, Patience Moyo, et al.Journal of the American College of Cardiology|January 25, 2023
Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone InhibitorsEfe Eworuke, Emily C Welch, Nicole Haug, et al.Drug Safety|May 20, 2021
Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and WarfarinEfe Eworuke, Laura Hou, Rongmei Zhang, et al.Pharmacoepidemiology and Drug Safety|November 4, 2022
A new analytic tool for assessing the impact of the US Food and Drug Administration regulatory actionsChristine Y Lu, Laura Hou, Joy Kolonoski, et al.Pageof 3